Newbury Pharmaceuticals Q1: Awaiting Commercial Takeoff - Redeye

Redeye provides a research update following the Q1 report published by Newbury yesterday. We make some slight adjustments to our estimates for operational expenditures, investments, and net sales. Accordingly, we update our fair value range with a revised base case valuation of SEK8.5 (SEK9) as we continue to have a positive outlook on the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/870714/newbury-pharmaceuticals-q1-awaiting-commercial-takeoff-2?utm_source=finwire&utm_medium=RSS